NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR M701 “CD3/EpCAM BISPECIFIC ANTIBODY”

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF CAFELKIBART “CCR8 MONOCLONAL ANTIBODY” FOR SECOND-LINE GASTRIC CANCER

VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF CULMERCICLIB CAPSULE “CDK2/4/6 INHIBITOR” FOR FIRST-LINE TREATMENT OF BREAST CANCER APPROVED FOR MARKETING

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026